Teva Pharmaceutical Industries Ltd TEVJF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TEVJF is a good fit for your portfolio.
News
-
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
-
Greenlight's David Einhorn pitches 'boring essential-chemicals business' Solvay
-
David Einhorn's Greenlight Capital adds Kenvue, ETFs and exits Southwestern Energy
-
Corcept Therapeutics Shares Slide Premarket on Loss in Teva Patent Suit
-
Corcept stock drops after drugmaker loses patent lawsuit against Teva
-
Biogen 'welcomes' EC decision to revoke CMAs for generic versions of Tecfidera
-
Teva Closes Collaboration Deal With Sanofi on IBD Treatment
-
Teva shares climb as third-quarter sales top estimates
Trading Information
- Previous Close Price
- $11.98
- Day Range
- $11.75–11.75
- 52-Week Range
- $7.03–15.87
- Bid/Ask
- $10.90 / $18.00
- Market Cap
- $13.31 Bil
- Volume/Avg
- 191 / 8,986
Key Statistics
- Price/Earnings (Normalized)
- 4.59
- Price/Sales
- 0.83
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Value
- Total Number of Employees
- 37,851
- Website
- https://www.tevapharm.com
Competitors
Valuation
Metric
|
TEVJF
|
NVS
|
RDY
|
---|---|---|---|
Price/Earnings (Normalized) | 4.59 | 14.13 | 19.91 |
Price/Book Value | 1.75 | 5.01 | 3.86 |
Price/Sales | 0.83 | 4.05 | 3.75 |
Price/Cash Flow | 9.13 | 13.45 | 15.29 |
Price/Earnings
TEVJF
NVS
RDY
Financial Strength
Metric
|
TEVJF
|
NVS
|
RDY
|
---|---|---|---|
Quick Ratio | 0.54 | 0.61 | 1.80 |
Current Ratio | 1.02 | 0.90 | 2.55 |
Interest Coverage | 0.39 | 11.32 | 46.52 |
Quick Ratio
TEVJF
NVS
RDY
Profitability
Metric
|
TEVJF
|
NVS
|
RDY
|
---|---|---|---|
Return on Assets (Normalized) | 6.70% | 13.39% | 15.57% |
Return on Equity (Normalized) | 39.00% | 31.09% | 21.70% |
Return on Invested Capital (Normalized) | 13.54% | 19.67% | 20.10% |
Return on Assets
TEVJF
NVS
RDY
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Fycbrtwgrw | Hlz | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Gxxqxnfpf | Rkxnzr | $69.1 Bil | |
HLN
| Haleon PLC ADR | Gzvccvnj | Bjqx | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Ffwksrx | Tcndl | $15.7 Bil | |
VTRS
| Viatris Inc | Hdxzjbcw | Cgl | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Jfdpcpxkt | Vkf | $12.4 Bil | |
CTLT
| Catalent Inc | Cmxlvgdz | Ngkkl | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Tghlzqkty | Sst | $4.5 Bil | |
CURLF
| Curaleaf Holdings Inc | Hjgjytbg | Myg | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Kwgzghlh | Nlzywc | $3.5 Bil |